- Home
- FRMI vs PCVX Comparison
FRMI vs PCVX Comparison
Compare FRMI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRMI | PCVX |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRMI | PCVX |
|---|---|---|
| Price | $8.11 | $56.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $29.50 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 6.8M | 1.0M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,427.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.18 | $28.09 |
| 52 Week High | $32.39 | $76.61 |
Technical Indicators
Market Signals| Indicator | FRMI | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 48.83 |
| Support Level | $7.23 | $42.30 |
| Resistance Level | $10.57 | $57.50 |
| Average True Range (ATR) | 0.90 | 2.96 |
| MACD | -0.17 | -0.68 |
| Stochastic Oscillator | 10.69 | 14.14 |
Price Performance
Historical ComparisonAbout FRMI Fermi Inc.
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.